Roche Acquires Inflazome for ~$450M
Shots:
- Inflazome to receive $450.31M as up front and is eligible to receive additional contingent payments based on the achievement of certain predetermined milestones
- The acquisition allows the Roche to get full rights to Inflazome’s portfolio consisting of pre/ clinical orally available small molecule NLRP3 inhibitors
- Roche will further advance the NLRP3 inhibitors across a wide variety of indications targeting the unmet medical needs across a wide variety of inflammatory diseases
Ref: PRNewswire | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com